BlackRock’s Teva Pharmaceuticals TEVA Stock Holding History

BlackRock’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-180,000	Closed	-$1.62M	–	5171
2020 Q3	$1.62M	Sell	180,000 -70,000	-28%	-$741K	﹤0.01%	3960
2020 Q2	$3.08M	Sell	250,000 -515,000	-67%	-$5.82M	﹤0.01%	3700
2020 Q1	$6.87M	Buy	765,000 +83,500	+12%	+$855K	﹤0.01%	3191
2019 Q4	$6.68M	Buy	681,500 +205,000	+43%	+$1.83M	﹤0.01%	3424
2019 Q3	$3.28M	Buy	476,500 +210,500	+79%	+$1.61M	﹤0.01%	3604
2019 Q2	$2.46M	Buy	266,000 +214,500	+417%	+$2.59M	﹤0.01%	3713
2019 Q1	$808K	Hold	51,500	–	–	﹤0.01%	3980
2018 Q4	$794K	Sell	51,500 -285,000	-85%	-$5.84M	﹤0.01%	3972
2018 Q3	$7.25M	Buy	+336,500	New	+$7.81M	﹤0.01%	3375
2018 Q2	–	Sell	-86,000	Closed	-$1.47M	–	5080
2018 Q1	$1.47M	Sell	86,000 -183,500	-68%	-$3.58M	﹤0.01%	3777
2017 Q4	$5.11M	Buy	+269,500	New	+$4.05M	﹤0.01%	3435
2016 Q2	–	Sell	-12,000	Closed	-$642K	–	3813
2016 Q1	$642K	Buy	+12,000	New	+$704K	﹤0.01%	1493

Other funds holding TEVA

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock's TEVA Position: Q1 2026 in Review

BlackRock increased its Teva Pharmaceuticals (TEVA) stake by 12% in Q1 2026, buying an estimated $220M and bringing the position to 65,136,464 shares worth $1.96B. The position accounts for 0.03% of the portfolio, ranked #423.

BlackRock first reported a position in TEVA in Q1 2014 and has held it in 49 quarters since. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

BlackRock held 65,136,464 shares of Teva Pharmaceuticals worth $1.96B as of Q1 2026.
BlackRock bought 6,833,776 Teva Pharmaceuticals shares in Q1 2026, an estimated $220M.
Teva Pharmaceuticals made up 0.03% of BlackRock's portfolio in Q1 2026, its #423 holding.
BlackRock first reported a position in Teva Pharmaceuticals in Q1 2014 and has held it in 49 quarters since.
651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.